Pharmaceutical intermediates are intermediate products generated through a series of chemical reactions during the synthesis of chemical drugs, and they serve as precursors for the further synthesis of active pharmaceutical ingredients (APIs). These intermediates do not possess full pharmacological activity themselves; rather, they must undergo subsequent processes such as molecular structure modification and purification before they can be transformed into APIs with therapeutic effects.

Core role:

Reducing Synthetic Complexity: The synthesis of complex drug molecules typically proceeds in a stepwise manner. Intermediates can break down a long-chain synthesis process into multiple simpler reaction units, thereby reducing the complexity of each individual reaction step. For example, the synthesis of paclitaxel involves more than 20 reaction steps, and each intermediate generated at every step provides a stable “building block” for subsequent reactions.

Enhancing Production Efficiency: Intermediates can be prefabricated on a large scale and key intermediate products can be stockpiled in advance, thereby avoiding the lengthy wait times associated with “de novo synthesis” during active pharmaceutical ingredient (API) production. For example, the intermediates “SM1” and “SM2” for the oral COVID-19 drug nirmatrelvir can be produced in bulk ahead of time, significantly shortening the emergency supply cycle for the API.

Controlling Costs and Risks: Some intermediates can be mass-produced by specialized chemical plants, offering greater cost advantages compared to in-house synthesis by pharmaceutical companies. Meanwhile, quality testing of intermediates can identify impurity issues at an early stage, thereby preventing costly failures in the subsequent synthesis of active pharmaceutical ingredients.